eISSN: 2473-0815
Submit manuscript...
Review Article Volume 13 Issue 2
Pioglitazone and NASH: A narrative review
Debmalya Sanyal
Received: July 26, 2025 | Published: September 25, 2025
Citation: Sanyal D. Pioglitazone and NASH: A narrative review. Endocrinol Metab Int J. 2025;13(2):72-75 DOI: 10.15406/emij.2025.13.00373
Abstract
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and fibrosis, primarily linked to metabolic syndrome. The rising prevalence of NASH reflects the global obesity epidemic, making it a significant public health concern. Current management strategies emphasize lifestyle modifications, including weight loss and dietary changes, alongside pharmacological interventions. Notably, pioglitazone, a thiazolidinedione, has demonstrated efficacy in improving liver histology by enhancing insulin sensitivity, although concerns regarding side effects persist. Semaglutide, a glucagon-like peptide-1 receptor agonist, also shows promise in promoting weight loss and improving liver outcomes. As research advances, novel therapeutic agents targeting various aspects of NASH are being explored. This review highlights the complexities of managing NASH within the broader context of metabolic disorders, underscoring the necessity for a comprehensive, individualized treatment approach to effectively combat this challenging condition
Keywords: nonalcoholic steatohepatitis, lifestyle modifications, pioglitazone, semaglutide, insulin sensitivity, pharmacological interventions
©2025 Sanyal. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.